Neurotransmitter receptor analysis in transgenic mouse models
- PMID: 15201460
- DOI: 10.1385/1-59259-804-8:231
Neurotransmitter receptor analysis in transgenic mouse models
Abstract
One of the characteristic findings in human Huntington's disease (HD) is the alteration of neurotransmitter receptors. To a remarkable degree, transgenic HD mouse models recapitulate neurotransmitter receptor alterations. Neurotransmitter receptors can be assessed at the protein level by using receptor-binding autoradiography. One can also measure levels of receptor messenger RNA with in situ hybridization (ISH), employing either oligonucleotide or ribonucleotide probes. Both of these techniques-receptor-binding autoradiography and in situ hybridization-yield quantitative and regionally specific information regarding neurotransmitter receptors. We describe techniques for performing receptor-binding autoradiography and two types of in situ hybridization using oligonucleotide and ribonucleotide probes. With receptor binding and ISH, one can obtain quantitative region-specific assessments of neurotransmitter receptor alteration, a key pathologic event in HD pathogenesis.
Similar articles
-
Alterations in dopamine and benzodiazepine receptor binding precede overt neuronal pathology in mice modelling early Huntington disease pathogenesis.Brain Res. 2005 Mar 28;1039(1-2):14-21. doi: 10.1016/j.brainres.2005.01.029. Brain Res. 2005. PMID: 15781041
-
Profiling neurotransmitter receptor expression in mouse gonadotropin-releasing hormone neurons using green fluorescent protein-promoter transgenics and microarrays.Neuroscience. 2005;132(3):703-12. doi: 10.1016/j.neuroscience.2005.01.035. Neuroscience. 2005. PMID: 15837132
-
Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease.J Neurochem. 2006 Feb;96(3):743-57. doi: 10.1111/j.1471-4159.2005.03588.x. Epub 2006 Jan 9. J Neurochem. 2006. PMID: 16405510
-
Visualization of neurotransmitter receptors and their mRNAs in the human brain.Arzneimittelforschung. 1992 Feb;42(2A):189-95. Arzneimittelforschung. 1992. PMID: 1316751 Review.
-
Striatal specificity of gene expression dysregulation in Huntington's disease.J Neurosci Res. 2006 Nov 1;84(6):1151-64. doi: 10.1002/jnr.21046. J Neurosci Res. 2006. PMID: 16983659 Review.
Cited by
-
Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.Brain Res. 2011 Jan 7;1367:310-8. doi: 10.1016/j.brainres.2010.08.099. Epub 2010 Sep 7. Brain Res. 2011. PMID: 20828543 Free PMC article.
-
Decreased dopamine receptor 1 activity and impaired motor-skill transfer in Dyt1 ΔGAG heterozygous knock-in mice.Behav Brain Res. 2015 Feb 15;279:202-10. doi: 10.1016/j.bbr.2014.11.037. Epub 2014 Nov 29. Behav Brain Res. 2015. PMID: 25451552 Free PMC article.
-
Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease.Neuroscience. 2007 Jun 29;147(2):354-72. doi: 10.1016/j.neuroscience.2007.03.010. Epub 2007 Jun 4. Neuroscience. 2007. PMID: 17544587 Free PMC article.
-
HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat.Neurochem Res. 2009 Jul;34(7):1343-53. doi: 10.1007/s11064-009-9914-y. Epub 2009 Jan 24. Neurochem Res. 2009. PMID: 19169813
-
Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.J Neurosci. 2006 Dec 27;26(52):13548-55. doi: 10.1523/JNEUROSCI.3554-06.2006. J Neurosci. 2006. PMID: 17192438 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources